Compare GSK plc (GSK) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Remitly Global Inc — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Remitly Global Inc trades at $24.13 (market cap $4.98B). The key difference: GSK plc is far larger — about 18.4× Remitly Global Inc's market cap, and GSK plc pays a 3.9% dividend while Remitly Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Remitly Global Inc for 53 Days on average.
| GSK | RELY | |
|---|---|---|
Market Cap | $91.88B | $4.98B |
Volume | 7,730,529 | 3,501,150 |
Sector | Health | Technology |
52-Week High | $61.18 | $26.92 |
52-Week Low | $43.24 | $12.20 |
Typical Hold Time | 93 Days | 53 Days |
Enterprise Value | $111.88B | $4.34B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
RELY trades at $23.52, up 2.57% today, with a bullish technical signal from moving averages. The company demonstrates strong fundamental momentum, with revenue growing from $654M in 2022 to $1.64B in 2025 and achieving profitability with net income of $67.93M. Recent Q2 2026 earnings significantly beat expectations, and positive news highlights partnerships and growth under new leadership.
The outlook is positive, supported by robust revenue growth, expanding profit margins, and a strong analyst consensus. Key risks include execution in a competitive digital payments space and market volatility. With a consensus price target of $30.50, representing significant upside, the stock presents a compelling opportunity for growth-oriented investors, though its current RSI suggests it may be overbought in the short term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
